Data published by Vir Biotechnology and a number of scientific collaborators suggests that the Covid-19 monoclonal antibody developed by the company and marketed with GlaxoSmithKline may be one of the few drugs of its kind to work well against the Omicron variant.
The study, a preprint that hasn’t been peer reviewed and was posted Tuesday on the website bioRxiv, found that Vir (ticker: VIR) and GlaxoSmithKline‘s (GSK) monoclonal antibody, sotrovimab, had “3-fold reduced potency” against Omicron compared with against the original